Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹3 Cr.
Stock P/E
-0.8
P/B
—
Current Price
₹3.4
Book Value
₹ 0
Face Value
10
52W High
—
52W Low
—
Dividend Yield
0%

RJ Bio-Tech Overview

Business

RJ Bio-Tech Ltd., operating in the Indian agriculture sector, primarily focuses on developing and marketing bio-technology-based solutions for agricultural applications. While specific product details require deeper review, companies in this space typically offer products like bio-fertilizers, bio-pesticides, plant growth promoters, and potentially enhanced seeds or animal feed supplements. The core business model involves R&D to develop these biological products, obtaining necessary regulatory approvals, and then manufacturing and distributing them to farmers, agricultural cooperatives, and other businesses within the agricultural value chain. The company makes money by selling these specialized agricultural inputs designed to improve crop yield, soil health, and pest resistance, often with a focus on sustainable and eco-friendly farming practices.

Revenue Mix

Without access to detailed financial reports, specific revenue breakdowns are not available. However, based on the company's sector and industry, potential key segments could include:

Bio-fertilizers: Products that enhance soil fertility and nutrient uptake.

Bio-pesticides: Biological agents used to control pests, diseases, and weeds.

Plant Growth Promoters: Substances that stimulate plant growth and development.

Other Agri-Inputs: Could potentially include specialized seeds or animal health/nutrition products if they leverage biotech in those areas.

The primary revenue would likely be generated from the sale of these biotech agricultural inputs.

Industry

The Indian agriculture sector is vast, fragmented, and heavily reliant on monsoon patterns, government policies, and farmer income. The agri-biotech segment is a growing niche within this larger sector, driven by increasing awareness of sustainable farming, demand for higher yields, and environmental concerns over chemical overuse. RJ Bio-Tech likely operates among a mix of established domestic players, smaller specialized firms, and potentially some larger multinational corporations. Its positioning would depend on its specific product portfolio, technological differentiation, distribution network strength, and market penetration in various agricultural regions of India. Without market share data, it's difficult to ascertain if it's a niche player, a regional leader, or a challenger.

MOAT

RJ Bio-Tech's potential competitive advantages (moats) could stem from:

Proprietary R&D and Intellectual Property: Development of unique microbial strains or formulations that offer superior efficacy or cost-effectiveness.

Regulatory Approvals: Having secured specific product approvals can create a barrier to entry, as the process for new biotech products can be lengthy and complex.

Distribution Network: A strong, established network reaching a broad base of farmers and dealers across different regions of India can be a significant advantage.

Farmer Trust & Brand Recognition: Consistent product performance can build brand loyalty among farmers, which is crucial in a market with many alternatives.

However, the strength and durability of these moats are dependent on the company's specific innovations and market execution, which are not readily apparent from the basic information.

Growth Drivers

Key factors that can drive growth for RJ Bio-Tech over the next 3-5 years include:

Increasing Demand for Sustainable Agriculture: Growing farmer and consumer preference for organic and eco-friendly farming practices.

Government Initiatives: Favorable government policies and subsidies promoting bio-inputs, higher productivity, and farmer income.

Technological Advancements: Continuous R&D leading to the introduction of more effective and efficient biotech products.

Food Security & Population Growth: Rising demand for food due to India's growing population, necessitating improved agricultural yields.

Expansion of Product Portfolio & Geographic Reach: Launching new products and expanding into new agricultural regions within India.

Risks

Monsoon Dependency: Agricultural output and farmer purchasing power are heavily influenced by monsoon rainfall, directly impacting demand for agri-inputs.

Regulatory & Policy Changes: Evolving regulations regarding bio-products, genetically modified crops, and agricultural subsidies can significantly impact operations and market access.

Competition: Intense competition from both domestic and international players offering similar or alternative products.

R&D Failure/Obsolescence: The risk of R&D investments not yielding commercially viable products or existing products becoming obsolete due to new technologies.

Raw Material Price Volatility: Fluctuations in the cost of raw materials necessary for producing bio-tech products.

Farmer Adoption Rates: New biotech products require farmer education and trust, and slow adoption can hinder growth.

Management & Ownership

In India, companies like RJ Bio-Tech Ltd. typically have a significant promoter (founding family or group) shareholding, indicating concentrated ownership and control. Management quality would depend on the experience, vision, and execution capabilities of the leadership team, as well as adherence to corporate governance standards. A detailed assessment would require reviewing their track record, educational background, and recent strategic decisions. The promoter group's long-term commitment to the business and their ability to navigate the complex agricultural landscape are crucial factors.

Outlook

RJ Bio-Tech operates in a fundamentally important and evolving sector in India. The growing emphasis on sustainable agriculture, coupled with the need for increased agricultural productivity, presents a positive long-term structural tailwind for companies offering advanced bio-inputs. If the company can consistently innovate, secure intellectual property, maintain strong regulatory compliance, and effectively expand its distribution network, it has potential for growth. However, the business is highly susceptible to external factors such as monsoon variability, commodity price fluctuations affecting farmer income, and dynamic government policies. Intense competition and the need for continuous R&D investment also pose ongoing challenges. Therefore, the outlook is cautiously optimistic, dependent on the company's ability to execute its strategy effectively amidst inherent industry volatilities and competitive pressures.

RJ Bio-Tech Share Price

Live · BSE · Inception: 2005
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

RJ Bio-Tech Quarterly Results

#(Fig in Cr.) Jun 2014 Sep 2014 Dec 2014 Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016
Net Sales 18 5 7 2 15 11 6 4
Other Income 0 0 0 0 0 0 0 0
Total Income 18 5 7 2 15 11 6 4
Total Expenditure 14 4 6 2 13 7 4 6
Operating Profit 3 1 2 -0 2 4 2 -3
Interest 1 1 1 1 1 1 1 1
Depreciation 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0
Profit Before Tax 2 0 1 -2 1 3 1 -4
Provision for Tax 0 0 0 0 0 0 0 0
Profit After Tax 2 0 1 -2 1 3 1 -4
Adjustments -2 -0 -1 2 -1 -3 -1 4
Profit After Adjustments 0 0 0 0 0 0 0 0
Adjusted Earnings Per Share 2.6 0.1 0.7 -1.8 1.6 3.4 1.2 -3.7

RJ Bio-Tech Profit & Loss

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
Net Sales 16 20 29 32 36 16 9 10 13 16 14 36
Other Income 0 0 0 0 0 0 0 0 0 0 1 0
Total Income 16 20 29 32 36 16 9 10 13 16 15 36
Total Expenditure 13 16 23 26 30 27 17 17 17 28 13 30
Operating Profit 3 4 6 6 6 -11 -8 -7 -3 -13 2 5
Interest 2 2 3 4 3 4 4 4 1 0 6 4
Depreciation 0 0 0 1 0 0 0 0 0 0 0 0
Exceptional Income / Expenses -0 -0 0 0 0 0 -9 0 0 -3 -0 0
Profit Before Tax 1 1 3 1 2 -15 -21 -12 -4 -16 -4 1
Provision for Tax 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Tax 1 1 3 1 2 -15 -21 -12 -4 -16 -4 1
Adjustments 0 0 0 0 0 0 0 0 0 0 -5 -1
Profit After Adjustments 1 1 3 1 2 -15 -21 -12 -4 -16 -9 0
Adjusted Earnings Per Share 0.8 1.9 3 1.5 2.4 -15.9 -21.9 -12.2 -4.4 -16.6 -4.3 2.5

RJ Bio-Tech Balance Sheet

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Shareholder's Funds 11 14 22 24 26 11 -10 -21 -26 -41 -50
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 3 3 2 2 0 1 5 5 5 4 3
Other Non-Current Liabilities 1 0 1 1 1 1 1 1 1 1 1
Total Current Liabilities 23 22 32 34 33 34 39 43 45 43 48
Total Liabilities 39 41 58 61 60 48 35 28 25 6 2
Fixed Assets 3 3 3 2 2 2 2 2 2 2 2
Other Non-Current Assets 0 0 0 1 1 1 1 1 0 0 0
Total Current Assets 32 35 52 56 55 44 32 24 22 4 0
Total Assets 39 41 58 61 60 48 35 28 25 6 2

RJ Bio-Tech Cash Flow

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Opening Cash & Cash Equivalents 1 1 0 1 0 -0 0 -0 0 -0 0
Cash Flow from Operating Activities -4 4 -5 2 6 0 -3 1 1 2 -5
Cash Flow from Investing Activities -3 -2 -2 -2 -1 -1 -1 -1 -1 -0 0
Cash Flow from Financing Activities 8 -3 8 -1 -5 1 3 -0 -0 -2 5
Net Cash Inflow / Outflow 0 -1 0 -0 -0 0 -0 0 -0 0 -0
Closing Cash & Cash Equivalent 1 0 1 0 -0 0 -0 0 -0 0 0

RJ Bio-Tech Ratios

# Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Earnings Per Share (Rs) 0.84 1.87 3.03 1.55 2.4 -15.86 -21.93 -12.18 -4.39 -16.56 -4.28
CEPS(Rs) 1.43 2.38 3.38 2.17 2.74 -15.64 -21.74 -12.02 -4.29 -16.47 -4.21
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 12.77 16.71 21.13 22.83 25.54 10.13 -11.5 -23.63 -28.1 -43.5 -53.17
Core EBITDA Margin(%) 20 20.13 20.37 17.84 16.8 -71.59 -90 -72.94 -26.02 -79.89 9.46
EBIT Margin(%) 17.61 18.35 19.22 15.98 15.9 -72.53 -189.91 -73.08 -25.19 -99.26 12.76
Pre Tax Margin(%) 4.99 6.57 10.01 4.62 6.34 -95.42 -233.67 -113.98 -31.06 -99.28 -29.14
PAT Margin (%) 3.37 6.57 10.01 4.62 6.31 -95.42 -233.67 -113.98 -31.06 -99.28 -29.14
Cash Profit Margin (%) 5.72 8.33 11.16 6.49 7.21 -94.11 -231.55 -112.5 -30.33 -98.7 -28.65
ROA(%) 1.64 3.3 5.83 2.46 3.76 -27.96 -50.28 -36.69 -15.63 -100.28 -104.09
ROE(%) 8.03 13.14 18.15 7.03 9.91 -88.93 0 0 0 0 0
ROCE(%) 11.57 12.02 14.47 10.86 11.73 -25.86 -51.57 -32.76 -19.75 -218.35 0
Receivable days 98.74 137.03 127.64 158.15 202.96 497.38 731.32 480.92 237.13 94.72 14.52
Inventory Days 422.65 369.31 310.89 340.38 305.79 617.29 761.77 491.48 380.6 179.09 0
Payable days 77.92 53.48 74.85 114.98 62.87 63.66 122.42 173.18 161 40.89 18.67
PER(x) 0 0 9.89 16.04 19.19 0 0 0 0 0 0
Price/Book(x) 0 0 1.42 1.09 1.8 2.47 -2.13 -0.82 -0.46 -0.15 -0.1
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 1.62 1.34 1.84 1.58 1.9 3.39 6.82 5.88 4.05 2.95 4
EV/Core EBITDA(x) 8.09 6.65 9.01 8.83 11.32 -4.73 -7.68 -8.22 -16.05 -3.69 27.91
Net Sales Growth(%) 19.73 23.33 44.48 10.42 13.55 -56.26 -43.75 14.35 32.06 18.24 -12.02
EBIT Growth(%) 21.34 28.52 51.31 -8.22 13.02 -299.62 -47.87 56.2 54.4 -365.06 111.31
PAT Growth(%) 31.55 140.27 120.35 -49.04 55.04 -761.74 -38.29 44.47 63.95 -277.31 74.18
EPS Growth(%) -1.11 121.64 62.11 -49.04 55.04 -761.75 -38.29 44.47 63.95 -277.31 74.18
Debt/Equity(x) 2.56 1.7 1.24 1.24 1.03 3.09 -3.41 -1.84 -1.57 -0.98 -1.01
Current Ratio(x) 1.41 1.54 1.61 1.63 1.68 1.27 0.81 0.56 0.49 0.09 0.01
Quick Ratio(x) 0.54 0.64 0.73 0.73 0.78 0.58 0.46 0.25 0.17 0.06 0.01
Interest Cover(x) 1.4 1.56 2.09 1.41 1.66 -3.17 -4.34 -1.79 -4.3 -6943.08 0.3
Total Debt/Mcap(x) 0 0 0.87 1.14 0.57 1.25 1.6 2.26 3.43 6.32 10.35

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -13% +12% -3% -1%
Operating Profit CAGR — — — -4%
PAT CAGR — — — 0%
Share Price CAGR +6% -6% -13% -20%
ROE Average 0% 0% 0% -3%
ROCE Average 0% -79% -64% -26%

RJ Bio-Tech Shareholding Pattern

Latest · Mar 2022
100% held
Promoters 60.32 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 39.68 %
# Sep 2017 Mar 2018 Sep 2018 Mar 2019 Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022
Promoter 60.2960.2960.2960.2960.2960.2960.2960.2960.3260.32
FII 0000000000
DII 0000000000
Public 39.7139.7139.7139.7139.7139.7139.7139.7139.6839.68
Others 0000000000
Total 100100100100100100100100100100

RJ Bio-Tech Peer Comparison

Agriculture Edit Columns

RJ Bio-Tech Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

RJ Bio-Tech Pros & Cons

Pros

  • Debtor days have improved from 40.89 to 18.67days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 0% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp